News

Cupron Performance Additives Announces New Applications for Cupron Sinerji™

Innovative antimicrobial solutions provider Cupron®, doing business as Cupron Performance Additives, announces expanded functionality for its recently introduced antimicrobial platform technology Cupron Sinerji.  Initially engineered as a copper-based formulation, Cupron® has now extended Cupron Sinerji’s  performance, cost, and color advantage to all metal ion chemistries commonly used for antimicrobial purposes.  Specifically, Cupron’s new platform technology delivers improved antimicrobial performance across commoditized antimicrobial metal ion types – copper, silver and zinc.

Cupron Sinerji incorporates adjuvants into the metal ion-based formulations, resulting in a custom, flexible technology engineered to harness synergistic effects to meet a wide range of product protection and antimicrobial performance objectives – from US EPA Treated Article Exemptions to unique and differentiated Public Health Claims.  FDA-regulated products may also incorporate customized Cupron Sinerji formulations.

Utilizing adjuvants, the technology delivers heightened efficacy against various organisms, including mold and mildew, improves color performance and increases manufacturing yields. It offers an efficient and adaptable solution for numerous markets and applications, demonstrating its versatility and innovative potential across all polymers and organisms.

“Expensive silver additives cause many brands to limit the amount used during manufacturing, diminishing the antimicrobial potency of the final products,” said Chris Andrews, CEO of Cupron Performance Additives.

Cupron Sinerji also imparts several non-cost benefits as well to a range of metal ion offerings: color flexibility, color stability, production efficiency and an improved sustainability profile across a range of substrates. With Cupron Sinerji, our partners will re-evaluate the economics and applications associated with microbial control and management. We are pleased to be the reason the market will expect more from antimicrobial additives.”

Recent News

03/27/2026

CvilleBioHub Appoints Nikki Hastings as President, Marking New Phase of Growth and Regional Leadership

CvilleBioHub today announced that its Board of Directors has appointed Nikki Hastings as President, recognizing her leadership in building the organization into a cornerstone of Central Virginia’s life sciences ecosystem and positioning it for continued growth and influence. The appointment comes as CvilleBioHub prepares to celebrate its 10th anniversary and marks one year since the

03/25/2026

Grenova Appoints New Chief Executive Officer to Lead Next Phase of Growth Across Global Automation Platform

Grenova today announced the appointment of Ted Hull as Chief Executive Officer. Hull will lead Grenova and its automation divisions, Peak Robotics and Peak Analysis & Automation (PAA), guiding the organization through its next phase of growth as a global platform delivering automation-ready solutions to laboratories world-wide. Grenova and its division partners are backed by

03/25/2026

Virginia Startups Raise Record $2.9 Billion in Venture Capital Investment in 2025 – Highest in Commonwealth History

Virginia Innovation Partnership Corp. (VIPC) today announced that the National Venture Capital Association (NVCA) reported Virginia attracted $2.9 billion in venture capital investment in 2025, marking an all-time high for the Commonwealth according to the 2025 Q4 Pitchbook-NVCA Venture Monitor Report.1 This record level of investment reflects the continued growth and momentum of Virginia’s startup